



Lucile Packard Children's Hospital

STANFORD UNIVERSITY MEDICAL CENTER

LPCH Antibigram Data from 2014 Isolates

Niaz Banaei, M.D., Director of Clinical Microbiology Laboratory
 Nancy Watz, CLS, Laboratory Reference Technologist, Antibiotics
 Diane Getsinger, CLS, Laboratory Reference Technologist, AFB/Mycology
 Integrated Pediatric Infectious Diseases Program Committee
 Kathleen Gutierrez M.D., Committee Chair

Values expressed are % susceptible

Gram Negative Bacilli	No. of Isolates (a)	Penicillins		Cephalosporins and Lactams					Carbapenems		Aminoglyc's			Others		Urines Only	
		Ampicillin (\$)	Piper/Tazobactam (\$\$\$)	Cefuroxime (IV) (\$)	Ceftriaxone (\$)	Ceftazidime (\$)	Cefepime (\$)	Aztreonam (\$\$\$)	Ertapenem (\$\$\$) ???	Meropenem (\$\$\$)	Amikacin (\$\$\$)	Gentamicin (\$\$\$)	Tobramycin (\$\$\$)	Ciprofloxacin (\$)	Co-trimoxazole (\$)	Cefazolin (\$)	Predicts 1st gen cephem
<i>Achromobacter xylosoxidans</i>	17(b)	-	94	-	-	71	18	0	-	88	0	0	0	24	100	-	-
<i>Acinetobacter baumannii</i>	5(b,c)	-	-	-	-	100	100	-	-	100	100	100	100	100	100	-	-
<i>Citrobacter freundii</i> complex	20(b)	0	68	0	65	65	100	-	94	100	92	84	84	95	60	0	86
<i>Enterobacter aerogenes</i>	22(b,c)	0	90	0	73	73	100	79	100	100	100	100	100	100	96	-	20
<i>Enterobacter cloacae</i> complex	62	0	79	0	65	74	100	77	70	100	100	97	97	98	83	0	25
<i>Escherichia coli</i>	300	44	97	91	93	96	96	96	99	100	100	90	90	87	65	78	93
<i>Klebsiella oxytoca</i>	37	0	88	86	92	100	100	80	100	100	100	94	94	91	89	75	68
<i>Klebsiella pneumoniae</i>	76	0	93	83	92	92	99	88	100	100	100	93	93	92	77	93	20
<i>Morganella morganii</i>	15(b,c)	0	-	0	93	100	100	-	100	-	-	93	100	80	80	-	-
<i>Proteus mirabilis</i>	27(b)	77	100	92	96	100	96	100	100	100	100	88	88	100	74	94	0
<i>Pseudomonas aeruginosa</i>	111	-	90	-	-	90	87	80	-	94	93	87	95	90	-	-	-
<i>Pseudomonas aeruginosa</i> (CF-mucoid) (d)	22(b)	-	Pip 77	-	-	91	82	77	Imp 73	77	-	-	95	59	-	-	-
<i>Pseudomonas aeruginosa</i> (CF-non-mucoid) (d)	53	-	Pip 88	-	-	88	88	83	Imp 75	77	-	-	88	83	-	-	-
<i>Salmonella</i> spp.	19(b,c)	83	-	-	84	-	-	-	-	-	-	-	-	53	95	-	-
<i>Serratia marcescens</i>	25(b)	0	95	0	88	96	100	95	100	100	100	100	96	96	100	-	0
<i>Stenotrophomonas maltophilia</i>	48	-	-	-	-	-	-	-	-	-	-	-	Levo 81	94	-	-	-

- (a) First isolate from each patient was included
- (b) Data from isolate totals <30 may be statistically unreliable
- (c) Includes isolates from 2013
- (d) Cystic fibrosis patient isolates tested by disk diffusion

Pip = Piperacillin; Imp = Imipenem;
 Levo = Levofloxacin

Values expressed are % susceptible

Gram Positive Cocci

	Number of Isolates	Beta-Lactams							Others										
		Oxacillin/Nafcillin (\$\$)		Penicillin or Ampicillin (\$)		1st Generation cephem (\$)		Cefuroxime (\$)	Ceftriaxone (\$)	Meropenem (\$\$\$)	Gentamicin (\$\$\$)	Ciprofloxacin (\$)	Clindamycin (a) (\$)	Erythromycin (\$\$)	Nitrofurantoin - urine (\$\$\$)	Co-trimoxazole (\$)	Vancomycin (\$\$)	Tetracycline (\$)	Linezolid (\$\$\$)
		%S	%I	%R															
Staphylococcus aureus	418	85	(b)	-	-	85	-	-	-	95	-	75	62	-	99	100	-	-	
MRSA only	63	0	0	-	-	0	-	-	-	90	-	59	23	-	100	100	95	-	
Staphylococcus lugdunensis	12(c,d)	100	(b)	-	-	100	-	-	-	100	-	100	100	-	100	100	-	-	
Staphylococcus sp., Coagulase-negative	83	37	(b)	-	-	37	-	-	-	64	-	60	30	-	72	100	-	-	
Enterococcus faecium	12(c,d)	-	25	0	75	-	-	-	-	-	-	-	-	-	42	-	75	-	
Enterococcus faecalis	23(c)	-	100	0	0	-	-	-	-	-	-	-	-	-	100	-	-	-	
Enterococcus sp. (not identified to species)	148	-	95	0	5	-	-	-	-	-	85	-	-	98	-	97	-	-	
Streptococcus group B (vag/anal screen)	236	-	100	0	0	-	-	-	-	-	-	66	-	-	-	-	-	-	
viridans group streptococci	38	-	76	21	3	-	-	97	-	-	-	89	56	-	-	100	-	-	
Streptococcus pneumoniae	33	-	73(e)	-	27	-	88	91(f)	90	-	-	90	82	-	73	100	-	-	

Drug cost: Please chose the appropriate antibiotic based on best spectrum of coverage and lowest cost. Costs are reflective of 1 day of therapy based on adult dosing and include drug levels and reformulations.

\$ = \$0-20
 \$\$ = \$20-50
 \$\$\$ = \$50-100
 \$\$\$\$ = >\$100

(a) Testing for inducible clindamycin resistance performed on all staphylococci and group B strep isolates
 (b) Sensitivity confirmed by PCR per request. (c) Data from isolate totals <30 may be statistically unreliable.
 (d) Includes isolates from 2013. (e) Based on meningitis interpretive criteria (more conservative). Nonmeningitis interpretation is 100%. (f) Ceftriaxone uses the meningitis interpretive criteria (more conservative).

Candida

Percent Susceptible By Broth Microdilution (YeastOne, Trek Diagnostics)	No. Tested	Amphotericin B (a) (\$\$\$\$)	Fluconazole (b) (\$)	Itraconazole (b) (\$)	Voriconazole (b) (\$\$\$\$)	Caspofungin (c) (\$\$\$)
Candida albicans	22(d,e)	100	95	95	95	100
Candida glabrata	10(d,e)	100	70	40	89	100
Candida parapsilosis	8(d,e)	100	100	100	100	100
Other Candida species	19(d,e)	100	(f)	100	100	90

Haemophilus influenzae

For infections with beta-lactamase producing H. influenzae: cefuroxime, cefotaxime, trimethoprim/sulfamethoxazole, amoxicillin/clavulanate, or azithromycin is recommended. Cefotaxime or ceftriaxone is drug of choice for CNS infections. At LPCH, 63% (36/57) of H. influenzae are ampicillin susceptible.

(a) Suggested Ampho Resistant breakpoint MIC > or = 2 mcg/ml. (b) Susceptible dose-dependent breakpoint MIC was used.
 (c) Consult Peds ID if Caspofungin being considered for treatment. (d) Data from isolate totals <30 may be statistically unreliable.
 (e) Includes isolates from 2013. (f) Species other than C. krusei are 100% susceptible; C. krusei is intrinsically resistant to fluconazole.